StockStory.org on MSN1d
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
The Manila Times1d
China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
RiverBender.com3d
Durbin, Warren, Welch, Sanders Demand Answers From Telehealth Companies Regarding Their Financial Relationship With Pfizer, Eli Lilly Amid Concerns
WASHINGTON, D.C. U.S. Senate Democratic Whip Dick Durbin (D-IL) sent letters to five telehealth companies that have held ...
Here’s How Eli Lilly and Company (LLY) Contributed to Parnassus Core Equity Fund’s Performance
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
MedPage Today4d
Topical JAK Inhibitor Active in Itchy Prurigo Nodularis
ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...
2 Stocks That Could Split Very Soon
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
Eli Lilly (LLY) Slid on Rare Revenue Miss in its 3Q Update
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
Eli Lilly’s three-year Ebglyss study leaves 50% of AD patients with clear skin
The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...
SHINE5dOpinion
Breakthroughs in Alzheimer's diagnosis and treatment portend multibillion-dollar industry
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...